Cargando…
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect p...
Autores principales: | Noaks, Elsa, Peticone, Carlotta, Kotsopoulou, Ekaterini, Bracewell, Daniel G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917474/ https://www.ncbi.nlm.nih.gov/pubmed/33718517 http://dx.doi.org/10.1016/j.omtm.2021.02.002 |
Ejemplares similares
-
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures
por: Wang, Xiaonan, et al.
Publicado: (2021) -
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020) -
T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy
por: Wada, Fumiya, et al.
Publicado: (2022) -
Leukapheresis and Hyperleukocytosis, Past and Future
por: Zhang, Dongdong, et al.
Publicado: (2021) -
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022)